Immune therapy for hard-to-treat membranous nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing a new kind of immune therapy, called UCAR-T, which uses reprogrammed white blood cells to help treat a severe type of kidney disease (membranous nephropathy) that has not improved with standard medicines. The goal is to see if this therapy can calm the immune attack on the kidneys and reduce protein loss in urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have confirmed primary membranous nephropathy (a type of kidney disease) that is high-risk, has not responded to standard treatments, or has come back after treatment.
- Your kidney function is okay: a calculated value (eGFR) of at least 45, and no end-stage kidney failure.
- Your blood counts and organ functions are within safe limits (like white blood cells, hemoglobin, platelets, liver and heart checks).
- You have no serious ongoing infections (like hepatitis B or C, HIV, or syphilis) and no diabetes that is out of control.
- You are willing to use effective birth control during the study and for 6 months after, and to follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
This early-stage trial tests a new type of immune cell therapy (UCAR T cells) for autoimmune diseases that have not responded to usual treatments. The therapy targets specific markers on immune cells to potentially calm the overactive immune response causing your illness.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
Hear when a new Refractory Idiopathic Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.